David A. Siegel Cure Vac N.V. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cure Vac N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 14,200 shares of CVAC stock, worth $46,860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,200Holding current value
$46,860% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CVAC
# of Institutions
86Shares Held
10.5MCall Options Held
75.5KPut Options Held
33.5K-
Black Rock Inc. New York, NY2.25MShares$7.44 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.65MShares$5.44 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$5.18 Million10.6% of portfolio
-
Ubs Group Ag577KShares$1.9 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL500KShares$1.65 Million0.01% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $619M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...